TriangleNCT00770120 · OUTCOME
Progression-Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Every 8 weeks until disease progression, up to 3 years.
What was measured
Progression-Free Survival was defined as the duration from the date of registration until the date of disease progression per RECIST or death due to any cause. Patients known to be alive without evidence of disease progression were censored at the date of last contact. Disease progression was defined as a \>= 20% increase over nadir in the sum of longest diameters of target lesions, unequivocal progression of non-target lesions in the opinion of the treating investigator, appearance of new lesions, symptomatic deterioration, or death due to disease
Groups in this outcome
Everolimus
Daily oral Everolimus 10 mg/day everolimus
| Group | Source count |
|---|---|
| Everolimus | 59 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Everolimus | 3.0 | Not reported | 1.8 | 3.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.8
- upper Limit
- 3.6
- value
- 3.0
- denoms
- counts
- group Id
- OG000
- value
- 59
- units
- Participants
- description
- Progression-Free Survival was defined as the duration from the date of registration until the date of disease progression per RECIST or death due to any cause. Patients known to be alive without evidence of disease progression were censored at the date of last contact. Disease progression was defined as a \>= 20% increase over nadir in the sum of longest diameters of target lesions, unequivocal progression of non-target lesions in the opinion of the treating investigator, appearance of new lesions, symptomatic deterioration, or death due to disease
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Daily oral Everolimus 10 mg/day everolimus
- id
- OG000
- title
- Everolimus
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Every 8 weeks until disease progression, up to 3 years.
- title
- Progression-Free Survival
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice